A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer

• Status: Active, not recruiting
• Trial end date: 2023-08-24

Summary

This study (also known as IMpassion050) will evaluate the efficacy and safety of atezolizumab compared with placebo when given in combination with neoadjuvant dose-dense anthracycline (doxorubicin) + cyclophosphamide followed by paclitaxel + trastuzumab + pertuzumab (ddAC-PacHP) in patients with early HER2-positive breast cancer (T2-4, N1-3, M0).

• Phase: Phase 3

Details

• Lead Sponsor: Hoffmann-La Roche
• Collaborator: Chugai Pharmaceutical
• Treatments: Ado-Trastuzumab Emtansine; Albumin-Bound Paclitaxel; Antibodies, Monoclonal; Atezolizumab; Cyclophosphamide; Doxorubicin; Liposomal doxorubicin; Maytansine; Paclitaxel; Pertuzumab; Trastuzumab